Market Capitalization (Millions $) |
8,151 |
Shares
Outstanding (Millions) |
71 |
Employees |
834 |
Revenues (TTM) (Millions $) |
1,437 |
Net Income (TTM) (Millions $) |
428 |
Cash Flow (TTM) (Millions $) |
343 |
Capital Exp. (TTM) (Millions $) |
108 |
Lantheus Holdings Inc
Lantheus Holdings Inc. is a publicly traded diagnostics and imaging company based in North Billerica, Massachusetts. It was formerly known as Bristol-Myers Squibb Medical Imaging and was spun off as a separate entity in 2008. Lantheus Holdings specializes in the development, production, and distribution of diagnostic imaging agents used in medical imaging, such as ultrasound, nuclear medicine, and magnetic resonance imaging (MRI). The company's flagship product is DEFINITY, an echocardiography agent that enhances the accuracy and clarity of ultrasound images of the heart. The company has a global presence, with offices and facilities located in the United States, Canada, Australia, and Puerto Rico. It also has a robust network of distribution partners and collaborations with other healthcare companies, academic institutions, and research organizations working toward advancing diagnostic imaging. In recent years, Lantheus Holdings has expanded its product portfolio through acquisitions and partnerships with other companies, including the acquisition of Progenics Pharmaceuticals in 2019. The company's primary focus is on improving patient outcomes through the development and commercialization of innovative diagnostic agents and technologies.
Company Address: 201 Burlington Road, South Building Bedford, 1730 MA
Company Phone Number: 671-8001 Stock Exchange / Ticker: NASDAQ LNTH
|